Research Topics
Genomes and Genes
| non hodgkin lymphomaSummarySummary: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Top Publications
Research Grants
| Scientific Experts
|
Detail Information
Publications
Revised response criteria for malignant lymphoma
Bruce D Cheson
Division of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
J Clin Oncol 25:579-86. 2007..Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies...Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
B D Cheson
National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 17:1244. 1999..We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and become more widely available...Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium
Nathaniel Rothman
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Lancet Oncol 7:27-38. 2006..We aimed to test this hypothesis using previously unpublished data from eight European, Canadian, and US case-control studies of the International Lymphoma Epidemiology Consortium (InterLymph)...Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy
Gary M Clifford
International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
J Natl Cancer Inst 97:425-32. 2005....CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh
University Clinic of Saarland, Homburg, Germany
Lancet Oncol 7:379-91. 2006..We aimed to compare CHOP-like chemotherapy and rituximab with CHOP-like chemotherapy alone in these patients...Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma
Heiko Schoder
Memorial Sloan Kettering Cancer Center, Department of Radiology, Nuclear Medicine Service, Box 77, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 23:4643-51. 2005..18)Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma. We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease...Exposure to pesticides as risk factor for non-Hodgkin's lymphoma and hairy cell leukemia: pooled analysis of two Swedish case-control studies
Lennart Hardell
Department of Oncology, Orebro University Hospital, Sweden
Leuk Lymphoma 43:1043-9. 2002..However, in multivariate analyses the only significantly increased risk was for a heterogeneous category of other herbicides than above...Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma
Qing Lan
Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH DHHS, MSC 7240, 6120 Executive Blvd, EPS 8109, Bethesda, MD 20892 7240, USA
Blood 107:4101-8. 2006..84; 95% CI = 1.79-8.22; P < .001). Further, the IL10 and IL4 SNP associations remained significant after adjusting for multiple comparisons. These results suggest that SNPs in Th2 cytokine genes may be associated with risk of NHL...Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma
Christine F Skibola
Division of Environmental Health Sciences, School of Public Health, 140 Earl Warren Hall, University of California, Berkeley, CA 94720 7360, USA
Cancer Epidemiol Biomarkers Prev 13:779-86. 2004....Non-Hodgkin lymphoma: diagnosis and treatment
Stephen M Ansell
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Mayo Clin Proc 80:1087-97. 2005..Patients with chemoresistant disease or whose disease relapses subsequently should be treated with novel experimental therapies...Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium
Anne Kricker
School of Public Health, University of Sydney, Sydney, New South Wales, Australia
Int J Cancer 122:144-54. 2008..Increased recreational sun exposure may protect against NHL...Persistent organochlorine chemicals in plasma and risk of non-Hodgkin's lymphoma
Anneclaire J De Roos
Fred Hutchinson Cancer Research Center and University of Washington Department of Epidemiology, Seattle, Washington 98109 1024, USA
Cancer Res 65:11214-26. 2005..02-1.79). Our results add to existing literature, which suggests that exposure to organochlorines contributes to non-Hodgkin's lymphoma risk; these risks were most apparent for certain PCBs and furans...Polychlorinated biphenyl levels in peripheral blood and non-Hodgkin's lymphoma: a report from three cohorts
Lawrence S Engel
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Res 67:5545-52. 2007..The results from these three cohorts suggest that concentrations of certain PCBs in blood are associated with increased risk of NHL...Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
Elizabeth C Moser
European Organization for Research on Treatment of Cancer EORTC Data Center, Brussels, Belgium
Blood 107:2912-9. 2006..In conclusion, patients are at long-term high risk of chronic heart failure after NHL treatment and need therefore life-long monitoring. In contrast, risk of coronary artery disease appeared more age dependent than treatment related...Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma
Matthew S Forrest
Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA 94720 7360, USA
Br J Haematol 134:180-3. 2006..67, 95% CI 0.45-0.99). These results suggest that variation in innate immune genes may alter NHL susceptibility...Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma
James R Cerhan
Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Blood 110:4455-63. 2007....Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)
Lindsay M Morton
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20852, USA
Blood 110:695-708. 2007....Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
Gary H Lyman
James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
Leuk Lymphoma 44:2069-76. 2003..13, 95% CI: 1.20-3.76). Such a model may permit the identification of patients at greatest risk of febrile neutropenia and, therefore, candidates for the selective prophylactic use of the hematopoietic growth factors...Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study
C Haioun
Hopital Henri Mondor, Assistance Publique Hopitaux de Paris AP HP, Creteil, France
J Clin Oncol 18:3025-30. 2000....Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial
Maurizio Martelli
Department of Cellular Biotechnology and Hematology, University La Sapienza of Rome, Italy
J Clin Oncol 21:1255-62. 2003..To evaluate the role of early intensification with high-dose therapy (HDT) and autologous stem-cell transplantation (ASCT) as front-line chemotherapy for patients with high-risk, histologically aggressive non-Hodgkin's lymphoma (NHL)...Non-hodgkin's lymphoma and agricultural use of the insecticide lindane
A Blair
Occupational Epidemiology Branch, National Cancer Institute, Bethesda, Maryland 20892 7364, USA
Am J Ind Med 33:82-7. 1998..5 to 1.2 and 1.3, respectively. Lindane does not appear to be a major etiologic factor in the development of non-Hodgkin's's lymphoma, although a small role cannot be ruled out...Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
P McLaughlin
Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
J Clin Oncol 16:2825-33. 1998..It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies...The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma
Jonathan D Tward
Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah 84112 5560, USA
Cancer 107:108-15. 2006..Survivors of non-Hodgkin lymphoma (NHL) are at increased risk for developing secondary malignancies. For the current study, the authors quantitated this risk in a group of NHL survivors over 30 years of follow-up...Agricultural risk factors for t(14;18) subtypes of non-Hodgkin's lymphoma
J C Schroeder
Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
Epidemiology 12:701-9. 2001..Results suggest that non-Hodgkin's lymphoma classification based on the t(14;18) translocation is of value in etiologic research...High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial
Harry C Schouten
Department of Internal Medicine, University Hospital Maastricht, The Netherlands
J Clin Oncol 21:3918-27. 2003....Soft-tissue sarcoma and non-Hodgkin's lymphoma clusters around a municipal solid waste incinerator with high dioxin emission levels
J F Viel
Department of Public Health, Faculty of Medicine, Besancon, France
Am J Epidemiol 152:13-9. 2000..g., a case-control study in which dioxins are measured in biologic tissues) before clusters of soft-tissue sarcoma and non-Hodgkin's lymphoma are ascribed to dioxin released by the municipal solid waste incinerator...VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group
G Santini
Department of Haematology, San Martino Hospital, Genova, Italy
J Clin Oncol 16:2796-802. 1998....Risk of non-Hodgkin lymphoma associated with occupational exposure to solvents, metals, organic dusts and PCBs (Australia)
Lin Fritschi
School of Population Health, University of Western Australia, Perth, Australia
Cancer Causes Control 16:599-607. 2005..We aimed to use accurate means to assess occupational exposures to solvents, metals, organic dusts and polychlorinated biphenyls (PCBs) in a case-control study...Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group
Thomas E Witzig
Department of Internal Medicine, Division of Hematology, Mayo Clinic 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 23:1103-8. 2005..The goals of this study were to assess the overall response rate (ORR) to rituximab in this patient population and to determine the time-to-progression (TTP) and time-to-subsequent-chemotherapy (TTSC)...Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma
T Nousiainen
Department of Medicine, Kuopio University Hospital and University of Kuopio, Finland
Eur J Haematol 62:135-41. 1999..On the other hand, our study suggests that natriuretic peptides are useful in the detection of subclinical left ventricular dysfunction in patients receiving doxorubicin therapy...Occupational exposure to solvents and the risk of lymphomas
Lucia Miligi
Istituto Toscano Tumori, Unit of Environmental and Occupational Epidemiology, Centre for Study and Prevention of Cancer, Via di S Salvi 12, 50135 Florence, Italy
Epidemiology 17:552-61. 2006..The present investigation aimed to evaluate the association between exposure to solvents and lymphomas (Hodgkin and non-Hodgkin) in a large population-based, multicenter, case-control study in Italy...Descriptive epidemiology of gastrointestinal non-Hodgkin's lymphoma in a population-based registry
K A Gurney
Leukaemia Research Fund Centre for Clinical Epidemiology, University of Leeds, UK
Br J Cancer 79:1929-34. 1999..Overall, the incidence of gastrointestinal NHL significantly increased by 2.7% per annum and was limited to the population aged over 50 years in this series...Skin cancer and non-Hodgkin's lymphoma as second malignancies. markers of impaired immune function?
K Hemminki
Department of Biosciences at Novum, Karolinska Institute, 141 57 Huddinge, Sweden
Eur J Cancer 39:223-9. 2003..0 for Hodgkin's disease; 3.6 for UADT as the first site). The high, and after certain sites, very high risks of second skin cancer and non-Hodgkin's lymphoma suggest that immune suppression may be a contributory mechanism...Cancer risk in people infected with human immunodeficiency virus in the United States
Eric A Engels
Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
Int J Cancer 123:187-94. 2008..These trends have led to a shift in the spectrum of cancer among HIV-infected persons...Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma
James R Cerhan
Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
Cancer Epidemiol Biomarkers Prev 17:3161-9. 2008....Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment
T A Davis
Stanford University, CA, USA
J Clin Oncol 18:3135-43. 2000....Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study
Elizabeth C Moser
EORTC Data Centre, Brussels, Belgium
Haematologica 91:1481-8. 2006..Second cancer has been associated with non-Hodgkin's Lymphoma (NHL) treatment, but few studies have addressed this issue considering specific treatments...Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)
G Jerusalem
Department of Medicine, University of Liege, Belgium
Ann Oncol 12:825-30. 2001..We undertook this study to determine factors influencing the detection of lesions by PET in low-grade NHL and to evaluate the utility of PET in this indication...Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma
Severin Daum
Department of Medicine I, Universitatsklinikum Benjamin Franklin, Hindenburgdamm 30, D 12200 Berlin, Germany
J Clin Oncol 21:2740-6. 2003..Intestinal non-Hodgkin's lymphomas are not well characterized. We therefore studied prospectively their clinical features and response to standardized therapy...Ultraviolet radiation exposure and risk of malignant lymphomas
Karin Ekstrom Smedby
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE 171 77 Stockholm, Sweden
J Natl Cancer Inst 97:199-209. 2005..One hypothesis holds that exposure to ultraviolet (UV) radiation increases lymphoma risk. We tested this hypothesis in a population-based case-control study in Denmark and Sweden...Non-Hodgkin's lymphoma and specific pesticide exposures in men: cross-Canada study of pesticides and health
H H McDuffie
Centre for Agricultural Medicine, University of Saskatchewan, Saskatoon, Saskatchewan
Cancer Epidemiol Biomarkers Prev 10:1155-63. 2001..We concluded that NHL was associated with specific pesticides after adjustment for other independent predictors...Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications
Christina A Clarke
Northern California Cancer Center, Union City, California, USA
Cancer Epidemiol Biomarkers Prev 13:138-43. 2004..Thus, overall NHL incidence and survival statistics from the early 1990s are probably accurate, but subtype-specific statistics could be substantially biased, especially because of high (15-20%) proportions of unclassified lymphomas...Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model
Francisco J Hernandez-Ilizaliturri
Department of Medicine, Roswell Park Cancer Institute Buffalo, New York 14263, USA
Clin Cancer Res 9:5866-73. 2003..The purpose of this work was to study the effect(s) of neutrophils on the in vivo antitumor activity of rituximab...Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms
E V Willett
Epidemiology and Genetics Unit, Department of Health Sciences, Seebohm Rowntree Building, University of York, UK
Br J Cancer 93:811-6. 2005..5-1.0) and increased with LEP -2548GA (OR = 1.3, 95% CI 1.0-1.7) and -2548AA (OR = 1.4, 95% CI 1.0-1.9), particularly for follicular lymphoma. These genetic findings, which were independent of BMI, were stronger for men than women...Non-Hodgkin lymphoma
Linda S Evans
Weston Park Hospital, S10 2SJ, Sheffield, UK
Lancet 362:139-46. 2003....Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy
B Vaughan Hudson
Department of Haematology, University College London School of Medicine, UK
Br J Cancer 69:1088-93. 1994....Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was
Sven Sandin
Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
Cancer Epidemiol Biomarkers Prev 15:1295-300. 2006..Insights into the descriptive epidemiology of NHL may shed light upon its elusive etiology...Pesticide exposures in children with non-Hodgkin lymphoma
J D Buckley
Department of Preventive Medicine, University of Southern California, Los Angeles, USA
Cancer 89:2315-21. 2000..However, to the authors' knowledge, data regarding pesticide exposures in children diagnosed with NHL have been lacking...Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project
T Rudiger
University of Wurzburg, Germany
Ann Oncol 13:140-9. 2002....Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy
J M Pluda
National Cancer Institute, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland
Ann Intern Med 113:276-82. 1990..As improved therapies for the treatment of HIV infection and its complications result in prolonged survival, non-Hodgkin lymphoma may become an increasingly significant problem...Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy
Renato Talamini
Servizio di Epidemiologia e Biostatistica, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy
Int J Cancer 110:380-5. 2004..In conclusion, HCV infection was associated with an increase in NHL risk, and the fraction of NHL cases attributable to HCV was 12.4% (range 6.3-18.5%)...The non-Hodgkin lymphomas: a review of the epidemiologic literature
Dominik D Alexander
Exponent Health Sciences Group, Exponent, Inc, Wood Dale, IL, USA
Int J Cancer 120:1-39. 2007..The extent to which the etiology of NHL types may differ is important to resolve in ongoing and future studies...Conservative management of gastric lymphoma: the treatment option of choice
Wolf Peter Schmidt
Department of Haematology, Allgemeines Krankenhaus St Georg, Hamburg, Germany
Leuk Lymphoma 45:1847-52. 2004..Survival was similar compared to patients initially treated with surgery. To avoid long-term sequelae after gastric resection, primary CHT is recommended as standard initial treatment in localized gastric lymphoma...Antidepressant medication use and non-Hodgkin's lymphoma risk: no association
Saira Bahl
Division of Preventive Oncology, Cancer Care Ontario, Toronto, Ontario, Canada
Am J Epidemiol 160:566-75. 2004..These findings do not support an increased risk of non-Hodgkin's lymphoma with antidepressant medication use...Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends
Shotaro Nakamura
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Cancer 97:2462-73. 2003..This study aimed to elucidate the clinicopathologic features of this disease and the influence of therapeutic modalities on the prognosis in Japanese patients..Tobacco and alcohol consumption and the risk of non-Hodgkin lymphoma
Eleanor V Willett
Department of Health Sciences, Leukaemia Research Fund Epidemiology and Genetics Unit, Seebohm Rowntree Building, University of York, York YO105DD, UK
Cancer Causes Control 15:771-80. 2004..The aim was to test whether non-Hodgkin lymphoma (NHL) is associated with smoking or alcohol...The risk of lymphoma development in autoimmune diseases: a meta-analysis
Elias Zintzaras
Department of Biomathematics, University of Thessaly School of Medicine, Larissa, Greece
Arch Intern Med 165:2337-44. 2005....Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL
Bing He
Departments of Pathology and Laboratory Medicine, Weill Medical College, Cornell University, New York, NY 10021, USA
J Immunol 172:3268-79. 2004..Thus, neutralization of BAFF and APRIL by soluble TACI and BCMA decoy receptors could be useful to dampen the accumulation of malignant B cells in NHL patients...Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma
Y Tsutsumi
Department of Internal Medicine, Hakodate Municipal Hospital 1 10 1, 041 0821 Minato cho, Hakodate, Japan
Ann Hematol 83:58-60. 2004..Lamivudine prophylaxis was effective, at least when rituximab was given to an HBsAg-positive patient with non-Hodgkin's lymphoma...Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women
L M Morton
Department of Epidemiology and Public Health, Yale University School of Medicine, 129 Church Street, Suite 700, New Haven, CT 06510, USA
Br J Cancer 89:2087-92. 2003..This research highlights the importance of distinguishing between NHL subtypes in future research on the aetiology of NHL...Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma
N Niitsu
First Department of Internal Medicine, Toho University School of Medicine, Tokyo Research Institute, Saitama Cancer Center, Saitama
Blood 97:1202-10. 2001..Therefore, it may provide useful information for clinicians to determine the appropriate therapy for each type of lymphoma...Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States)
Ikuko Kato
Department of Environmental Medicine, New York University of School of Medicine, New York, NY, USA
Cancer Causes Control 13:965-74. 2002..To examine whether exposures to anti-inflammatory and non-narcotic analgesic drugs are associated with risk of non-Hodgkin's lymphoma (NHL)...Clinical significance of nm23-H1 proteins expressed on cell surface in non-Hodgkin's lymphoma
N Niitsu
Department of Hematology and Internal Medicine IV, Kitasato University School of Medicine, Sagamihara shi, Kanagawa, Japan
Leukemia 17:196-202. 2003..The nm23-H1 protein appears to be intimately related to biological aggressiveness of lymphoma and, therefore, might be a molecular target of NHL treatment...Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma
T Kewalramani
Department of Medicine, Lymphoma and Hematology Services, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Bone Marrow Transplant 32:673-9. 2003....Agricultural use of organophosphate pesticides and the risk of non-Hodgkin's lymphoma among male farmers (United States)
B L Waddell
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
Cancer Causes Control 12:509-17. 2001..Associations, however, between reported use of diazinon and NHL, particularly diffuse and small lymphocytic lymphoma, among subjects providing direct interviews are not easily discounted...Cohort mortality study of Philadelphia firefighters
D Baris
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20892, USA
Am J Ind Med 39:463-76. 2001..Fire fighters are exposed to a wide variety of toxic chemicals. Previous studies have reported excess risk of some cancers but have been limited by small numbers or little information on employment characteristics...Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study
James R Cerhan
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
Am J Epidemiol 156:527-35. 2002..The opposite associations of body mass index with small lymphocytic lymphoma versus B-CLL may be a chance finding but, if confirmed, would suggest different etiologies for these malignancies...Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
Greg L Plosker
Adis International Limited, Mairangi Bay, Auckland, New Zealand
Drugs 63:803-43. 2003..g. bronchospasm, hypotension). These reactions are usually reversible with appropriate interventions and supportive care but there have been rare reports of fatalities...Organochlorines and risk of non-Hodgkin lymphoma
John J Spinelli
BC Cancer Agency, Vancouver, British Columbia, Canada
Int J Cancer 121:2767-75. 2007..lowest quartile OR = 2.68, 95% confidence interval = 1.69-4.24). Our results provide further evidence that organochlorines contribute to NHL risk...Haematopoietic cancer and medical history: a multicentre case control study
P Vineis
Unit of Cancer Epidemiology, Ospedale S Giovanni, Torino, Italy
J Epidemiol Community Health 54:431-6. 2000..Other associations (diabetes, tonsillectomy, autoimmune diseases) have been inconsistently reported...Operative and conservative management of primary gastric lymphoma: interim results of a German multicenter study
N A Willich
Department of Radiotherapy, University of Munster, Munster, Germany
Int J Radiat Oncol Biol Phys 46:895-901. 2000..Aim of study was the further standardization of operative and conservative treatment modalities...FDG-PET/CT in re-staging of patients with lymphoma
L S Freudenberg
Clinic and Policlinic for Nuclear Medicine, University of Essen, Essen, Germany
Eur J Nucl Med Mol Imaging 31:325-9. 2004..02) and has additional benefit over FDG-PET alone due to exact anatomical localisation. We conclude that FDG-PET/CT imaging is accurate in re-staging lymphoma and offers advantages over separate FDG-PET and CT imaging...ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
Felix Reyes
Hopital Henri Mondor, Assistance Publique Hopitaux de Paris, Creteil, France
N Engl J Med 352:1197-205. 2005..To determine the optimal therapy for nonelderly persons with low-risk localized lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone...Prognostic factors in non-Hodgkin lymphoma stage I treated with radiotherapy
H Hagberg
Department of Oncology, University of Uppsala, Sweden
Acta Oncol 28:45-50. 1989..e. highgrade NHL. This study indicates that large nodal lymphomas and some extranodal sites belong to this group...Alcohol, tobacco and recreational drug use and the risk of non-Hodgkin's lymphoma
R A Nelson
Department of Preventive Medicine, School of Medicine, University of Southern California, Los Angeles 90033, USA
Br J Cancer 76:1532-7. 1997..8, 95% confidence limits = 1.2-28.4); among these drugs, cocaine use appeared to account for the elevated risk of NHL among men based on multivariable analyses...Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study
Mark P Purdue
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892 7240, USA
Carcinogenesis 28:704-12. 2007..06, 95% CI=0.88-4.83; trend test, P=0.02). Our findings offer further evidence that variation in the IL10 and TNF loci influences NHL risk. Additional studies are needed to clarify the genetic and biologic basis for these relationships...Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium
Karin Ekstrom Smedby
Department of Medicine, Clinical Epidemiology Unit, Karolinska University Hospital, SE 171 76 Stockholm, Sweden
Blood 111:4029-38. 2008..Thus, specific autoimmune disorders are associated with NHL risk beyond the development of rare NHL subtypes in affected organs. The pattern of associations with NHL subtypes may harbor clues to lymphomagenesis...Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness
D N Aryee
Children s Cancer Research Institute, St Anna Kinderspital, Vienna, Austria
Br J Cancer 74:1693-8. 1996..No mutation was found by this screening. Our results suggest a role for nm23-H1 expression in the disease aggressiveness of lymphomas...Second primary cancers among 109 000 cases of non-Hodgkin's lymphoma
P Brennan
International Agency for Research on Cancer, 69008 Lyon, France
Br J Cancer 93:159-66. 2005..Bidirectional effects for several cancer sites of potential viral origin argue strongly for a role for immune suppression in NHL...Sun exposure may protect against non-Hodgkin lymphoma: a case-control study
Ann Maree Hughes
School of Public Health, The University of Sydney, Australia
Int J Cancer 112:865-71. 2004..Increasing evidence that vitamin D may protect against cancer makes UV-mediated synthesis of vitamin D a plausible mechanism whereby sun exposure might protect against NHL...A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma
C Burton
University College London and CRUK Clinical Trials Centre, 222 Euston Road, London NW1 2DA, UK
Br J Cancer 94:806-13. 2006..There was no significant difference in the failure-free, progression-free or overall survival with the addition of G-CSF...The epidemiology of non-Hodgkin's lymphoma
Susan G Fisher
Division of Epidemiology, Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 644, New York 14642, USA
Oncogene 23:6524-34. 2004..We must build on our current knowledge regarding the etiology of NHL in order that prevention, treatment, and ultimately, cure of this malignancy becomes a reality...Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy
O Kirk
EuroSIDA Coordinating Centre, Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark
Blood 98:3406-12. 2001..After starting HAART, patients with insufficient immunologic and virologic responses were at highest risk of NHL...Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma
Olaf Weingart
Cochrane Haematological Malignancies Group Department of Internal Medicine 1, University Hospital of Cologne, Kerpener Street 62, D 50924 Cologne, Germany
J Natl Cancer Inst 99:E1. 2007Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma
E Hardell
Department of Oncology, Orebro Medical Center, Sweden
Leuk Lymphoma 42:619-29. 2001..Also for the "sum of immunotoxic PCBs" increased risk was found in that group (OR=6.4, CI=1.9-24). Subdivision of NHL in histological types yielded highest risks for low-grade B-cell NHL...Ultraviolet radiation and incidence of non-Hodgkin's lymphoma among Hispanics in the United States
Shasa Hu
Department of Dermatology and Cutaneous Surgery, Sylvester Cancer Center, University of Miami School of Medicine, Miami, Florida, USA
Cancer Epidemiol Biomarkers Prev 13:59-64. 2004..Additional studies should be conducted to clarify whether sunlight exposure contributes to the development of NHL...Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database
Andrea Altieri
Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany
Blood 106:668-72. 2005..The patterns of risks in parents and siblings support the hypothesis of an autosomal-dominant component for diffuse large B-cell NHL and a recessive one for follicular NHL...Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing
Kristen H Taylor
Department of Pathology and Anatomical Sciences, Ellis Fischel Cancer Center, University of Missouri Columbia, Columbia, Missouri, USA
Cancer Res 67:8511-8. 2007..This new generation of methylome sequencing will provide digital profiles of aberrant DNA methylation for individual human cancers and offers a robust method for the epigenetic classification of tumor subtypes...Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
I F Khouri
Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
J Clin Oncol 16:2817-24. 1998....Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma
Osnat Bairey
Institute of Hematology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel
Eur J Haematol 76:384-91. 2006....A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
Oliver W Press
Fred Hutchinson Cancer Research Center, D3 190, 1100 Fairview Ave, Seattle, WA 98109, USA
Blood 102:1606-12. 2003..This novel treatment appears promising compared with the SWOG's historical experience using CHOP alone and is currently being compared with CHOP plus rituximab in a randomized phase 3 trial (S0016)...Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials
Gregory A Wiseman
Nuclear Medicine, Department of Radiology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
J Nucl Med 44:465-74. 2003..Dosimetry and pharmacokinetic data from 4 clinical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) were combined and assessed for correlations with toxicity data...Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe
Peter Adamson
Epidemiology and Genetics Unit, Department of Health Sciences, University of York, Seebohm Rowntree Building, Alcuin Area 3, York YO10 5DD, UK
Eur J Cancer 43:391-401. 2007..Overall, there are increases in the numbers of NHL registrations made with a corresponding decrease in HL. In recent history, however, there is a suggestion that the rate of increase is less and stable...Association of HLA alleles with non-Hodgkin's lymphoma in Korean population
Hee Baeg Choi
Catholic Hemopoietic Stem Cell Bank, Department of Microbiology, College of Medicine, The Catholic University of Korea, 505 Banpo Dong, Seocho Ku, Seoul, South Korea
Int J Hematol 87:203-9. 2008..Also, the B51-DRB1*09-DQB1*03 haplotype was significantly increased in the patients with NHL. These results suggest that some genes in HLA-B*51-DRB1*09-DQB1*03 haplotype may contribute to NHL susceptibility in the Korean population...[Non Hodgkin lymphoma in the North-East Bosnia--changes in biological aggressiveness and primary presentation of the disease]
Alma Halilbasic
Univerzitetski centar Tuzla, Trnovac
Med Arh 60:78-83. 2006..It especially illustrates the post war period from 1998 to 2002...Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
Marc Andre
Hematology Department, Centre Hospitalier Notre Dame et Reine Fabiola, Grand Rue 3, 6000 Charleroi, Belgium, E mail
Blood 103:1222-8. 2004..9; P <.001). With a long follow-up, the ACVBP regimen was highly effective for the treatment of aggressive NHL. Increases occurred in secondary MDS/AML and in lung cancer among men...Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium
Christine F Skibola
237A Hildebrand Hall, School of Public Health, University of California, Berkeley, Berkeley, CA 94720 7360, USA
Am J Epidemiol 171:267-76. 2010..04). These findings strengthen previous results for DLBCL and the LTA 252A>G/TNF -308A locus and provide robust evidence that these TNF/LTA gene variants, or others in linkage disequilibrium, are involved in NHL etiology...Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma
J F Modiano
Leukemia 21:184-7. 2007Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis
J Askling
Clinical Epidemiology Unit M9 01, Department of Medicine, Karolinska University Hospital Solna, SE 171 77 Stockholm, Sweden
Ann Rheum Dis 64:1765-8. 2005..Polymyalgia rheumatica (PMR) and temporal arteritis (giant cell arteritis, GCA) are common inflammatory conditions treated with steroids as single immunosuppressive therapy, but data on lymphoma risk in GCA/PMR are limited...Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection
Michele Spina
Division of Medical Oncology A, National Cancer Institute, Aviano, Italy
Clin Infect Dis 38:142-4. 2004..4 for HIV-infected patients vs. 1 for HIV-negative patients; P=.24). Therefore, the achievement of complete remission should be the main goal in the treatment of patients with HIV-NHL...Interstitial pneumonitis related to rituximab therapy
Catherine Burton
N Engl J Med 348:2690-1; discussion 2690-1. 2003
Research Grants
- Parental age at birth and risk of adult-onset cancer in female offspringYani Lu; Fiscal Year: 2013..The long-term goal of the research is to explore biomarkers that link parental age and cancer risk to clarify etiology, and thus provide potential targets for prevention. ..
- Optimization of adoptive immunotherapy with autologous CD20-specific T cellsBrian Till; Fiscal Year: 2013....
- Non-Hodgkin lymphoma in women: reproductive, hormonal and genetic factorsPaige M Bracci; Fiscal Year: 2011....
- GB Virus C and Non-Hodgkins Lymphoma Risk and PrognosisJack T Stapleton; Fiscal Year: 2013..Regardless of the results obtained, this study has the potential to have a great impact on public health regarding transfusion medicine, and potentially in the clinical management of NHL patients. ..
- Murine Models for Mantle Cell Lymphoma: The role of tumor initiating cells (TIC)Richard J Ford; Fiscal Year: 2010....
- Genetics of risk of chemotherapy-induced cardiotoxicity in cancer survivorsPeter Demant; Fiscal Year: 2013..This will have strong prospects to uncover novel pathways influencing ACT and open the way for definition of individual ACT pathogenesis in mice and humans. ..
- The effects of hepatitis C virus (HCV) E2 protein on host immunomodulationJack T Stapleton; Fiscal Year: 2013..Identification and characterization of this HCV E2 - lymphocyte interaction may contribute to the development of novel therapeutic and/or vaccine approaches to HCV, and potentially to related viruses within the Flaviviridae. ..
- Vitamin D and Non-Hodgkin Lymphoma PrognosisJennifer L Kelly; Fiscal Year: 2012..There are an estimated 20,000 annual NHL deaths, though epidemiology of NHL prognosis remains poorly understood. Vitamin D is a modifiable lifestyle factor, and closer evaluation of its role in NHL prognosis is warranted. ..
- Molecular epidemiology of non-Hodgkin lymphoma prognosis and preventionSophia Wang; Fiscal Year: 2013..Public health relevance: successful completion of this study will contribute to the understanding of host genetic variation and tumor markers in NHL survival. ..
- Trial of mesna to prevent doxorubicin-induced plasma protein oxidation and TNFa rJeffrey A Moscow; Fiscal Year: 2012....
- Genotyping and Phenotyping the Hepatitis C Drug Target NS5AROBERT T STRIKER; Fiscal Year: 2011..This database will catalog VA strains of HCV that need to be targeted by antivirals like cyclophilin inhibitors as well as others that are currently being investigated mostly outside the VA. ..
- Alpha Radioimmunotherapy for Lymphoma TreatmentBRENDA MARIE SANDMAIER; Fiscal Year: 2013..We anticipate that the information from these studies will allow rapid translation of the optimized promising RIT strategy using 211At-anti-CD45 MAb into our clinical RIT HCT program for NHL. ..
- 1H NMR STUDIES OF NON-HODGKINS LYMPHOMAJerry D Glickson; Fiscal Year: 2012..Here we are developing much more sensitive 1H NMR methods that can be used for early detection of response in all NHL patients. The same methods should be applicable to other prevalent forms of human cancer. ..
- Targeted therapy of pancreatic cancer with in vivo radionuclide generatorEkaterina Dadachova; Fiscal Year: 2012..If successful, this approach offers the possibility of cure for PCa. ..
- Genetic Susceptibility to Non-Hodgkins LymphomaChristine F Skibola; Fiscal Year: 2012....
- Inhibitors of IgH Gene Enhancers for the Treatment of Multiple MyelomaFRANK W MARCOUX; Fiscal Year: 2013..In our estimation, this therapeutics could have an impact on more than 100,000 new cancer cases that are diagnosed each year in the U.S. ..
- Immune complexes: origins and effects in HCV infectionLynn B Dustin; Fiscal Year: 2013..Our group is uniquely qualified to perform this study because of our expertise in HCV immunology and virology, and our ready access to viruses, viral proteins, and patients for study. ! ..
- Anthraycline-related cardiotoxicity in long-term survivors of lymphomaSARO ARMENIAN; Fiscal Year: 2013....
- CD20-targeted IL-15 immunotherapeutic for B-cell malignanciesHing C Wong; Fiscal Year: 2012....
- Functional analysis of leukemic CREBBP mutationsCharles G Mullighan; Fiscal Year: 2013..The translational impact of the results will be to enhance the knowledge-driven therapeutic use of glucocorticoids and HDACi to treat leukemia based on tumor cell genotype. ..
- Elucidating the Chemistry and Biology of Nucleic Acid Cytidine Deaminases in HIVRAHUL MANU KOHLI; Fiscal Year: 2013..abstract_text> ..
- Cancer risk after renal transplant in autoimmune diseaseRosalind Ramsey-Goldman; Fiscal Year: 2013....
- The Role of NPM-ALK Signaling in Tumor Cell MetabolismSCOTT RP MCDONNELL; Fiscal Year: 2012..The goal of this project is to determine how cells that express NPM- ALK proliferate and survive in order to identify new strategies for treatment. ..
- Molecular Epidemiology of NHL and CLLJames R Cerhan; Fiscal Year: 2012....
- 1st International Symposium on Childhood, Adolescent and Young Adult Hodgkin LympMonika Metzger; Fiscal Year: 2011....
- Pesticide Exposure and Childhood Cancer StudyBeate R Ritz; Fiscal Year: 2012..California children diagnosed with certain cancers (acute myeloid leukemia, acute lymphoblastic leukemia, non Hodgkin lymphoma, astrocytoma, primitive neuroectodermal tumors, Wilms tumor, soft tissue sarcomas) and population-based ..
- A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphomaBrenda M Birmann; Fiscal Year: 2013....
- CTCL immunobiology: lessons from alemtuzumabRACHAEL ANN CLARK; Fiscal Year: 2013..Our work will also provide critical insights into human immunobiology, providing the first evidence in humans that TCM are migratory, TEM are nonmigratory, and that TEM can provide immune protection of the skin in the absence of TCM. ..
- Resequencing and Functional Studies to Identify Causal Gene Variants of LymphomaChristine F Skibola; Fiscal Year: 2013..Thus, the identification of causal gene variants in this region for lymphoma may also prove helpful in understanding other diseases sharing common susceptibility loci. ..
- Detection of Light Chain Restriction in non-Hodgkin Lymphoma by a Novel RNA In SiXiao Jun Ma; Fiscal Year: 2012..Detection of restricted immunoglobulin light chain expression is a molecular ancillary tool to resolve ambiguous lymphoproliferative disorders. The proposed product based on RNAscope will provide superior sensitivity to current methods. ..
- Engineering Stem Cell Niches to Guide DifferentiationDANIELLE A TSOU; Fiscal Year: 2011..The hematopoietic differentiation pathways in the murine system have been established, and a specific ESC line will allow simultaneous monitoring of mesoderm and hematopoietic differentiation. ..
- Proteomic analysis of api2-MALT1 positive gastric MALT lymphomaKojo S J Elenitoba-Johnson; Fiscal Year: 2013....
- Impact of Lifestyle with Tumor Pathways and Microenvironment on Lymphoma SurvivalANDREW M contact EVENS; Fiscal Year: 2010..The results will provide new insights into improved disease prognostication, and ultimately lead to better treatment selection. ..
- Lifestyle Factors and Lymphoma: An Asia Cohort Consortium Pooling ProjectBrian C H Chiu; Fiscal Year: 2013..abstract_text> ..
- Role of MLL2 Gene Inactivation in B cell Non Hodgkin LymphomaLaura Pasqualucci; Fiscal Year: 2013....
- Discovery of New Treatment Options for EBV-associated Lymphoma and PTLDRICHARD M LONGNECKER; Fiscal Year: 2012..Our specific goals are to identify drugs that target EBV latent infections and EBV-associated lymphomas that occur in the human host by using inhibitors of cell proteins targeted by EBV. ..
- The Ohio State Blood and Marrow Transplant Reseach ConsortiumSteven M Devine; Fiscal Year: 2013..We seek to test new agents following AHCT in patients with DLCL to determine if we can lower the risk of relapse and improve the lives of these patients. ..
- Molecular Epidemiology of Nutrition and Cancer in the Multiethnic Cohort StudyLaurence N Kolonel; Fiscal Year: 2010..This P01 should add substantially to knowledge of cancer etiology, as well as to an understanding of the basis for ethnic/racial disparities in cancer occurrence. ..
- TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICSJacqueline E Payton; Fiscal Year: 2013..abstract_text> ..
- Beyond GWAS: the next 10 years of InterLymphWendy Cozen; Fiscal Year: 2011....
- City of Hope Lymphoma SPOREStephen J Forman; Fiscal Year: 2013..This Lymphoma SPORE will also support a Developmental Research Program and a Career Development Program to foster the advancement of pilot translational research projects and young investigators focused on lymphoma. ..
- Regulation of B cell development by the proto-oncogene LRF/PokemonTakahiro Maeda; Fiscal Year: 2013....
- Host Defense Regulation and Viral OncogenesisGlen N Barber; Fiscal Year: 2013..PROJECT II, William Harrington, Jr., M.D.: Host Defense regulation by HTLV-1. PROJECT III, Enrique Mesri, Ph.D.: HHV8 (KSHV)-Mediated Regulation of Host Defense. ..
- The Pathogenesis of Autoimmunity in Hepatitis C Virus InfectionEdgar D Charles; Fiscal Year: 2012..Relevance: An understanding of how HCV causes B cell dysregulation could lead to improved treatments for HCV MC. Moreover, these studies could further our understanding of viral-induced autoimmunity and malignancy. ..
- Columbia-South Africa Training Program for Research on HIV-associated MalignanciAlfred I Neugut; Fiscal Year: 2013....
- Cancer Risk: Advancing knowledge in systemic rheumatic diseaseRosalind Ramsey-Goldman; Fiscal Year: 2013....
- Proteomic biomarkers of ALK+ lymphomaMegan S Lim; Fiscal Year: 2013..Collectively, our studies will lead to identification of protein biomarkers of NPM/ALK lymphomas that will be important for the diagnostic assessment, treatment and monitoring of patients with ALCL. ..
- Multi-functional Nanocarrier against Canine LymphomaKit S Lam; Fiscal Year: 2013..These nanotherapeutics will be evaluated for their anti-tumor efficacies in transgenic mouse lymphoma model and in companion dogs with spontaneous lymphomas. ..
- A MULTILEVEL APPROACH TO ENERGY BALANCE AND CANCER ACROSS THE LIFECOURSEGraham A Colditz; Fiscal Year: 2013..To address these aims, we propose four research projects and five cores that form a cohesive, transdisciplinary center focused on research, training/career development, and dissemination. ..
- Fourth International Symposium on Childhood, Adolescent and Young Adult Non-HodgkMitchell S Cairo; Fiscal Year: 2012....
- Models for cumulative spatial-temporal assessment of non-Hodgkin lymphoma riskDAVID CHARLES WHEELER; Fiscal Year: 2013....
- BIOMEDICAL (BASIC)ANNECLAIRE DEROOS; Fiscal Year: 2009..After carefully characterizing this pathway, these data will become a useful resource for future studies of NHL in the WHI. ..
- Reducing Complement Inhibition to Treat Leukemia and LymphomaDARRICK ALBERT CARTER; Fiscal Year: 2013....
- MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCLHao Wu; Fiscal Year: 2013..abstract_text> ..
- Multiple Myeloma Consortium Study of Occupational Exposures and Family HistoryAnneclaire J De Roos; Fiscal Year: 2013....
- Quantitative SPECT for Targeted Radionuclide TherapyEric C Frey; Fiscal Year: 2013..These methods would provide substantial improvements in 3D dose estimates, and thus in the ability to predict and understand biological response and optimize therapeutic doses for TRT. ..
- Role of constitutive androstane receptor in cyclophosphamide-based chemotherapyHongbing Wang; Fiscal Year: 2013..Improved understanding of the underlying mechanism(s) associated with hCAR-mediated enhancement of the anticancer activity of CPA may ultimately benefit the development of new therapeutic strategies. ..
- Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapyEdmund A Rossi; Fiscal Year: 2011..The lessons learned from this project may eventually lead to the development of additional MAb-IFNa for therapy of a variety of hematopoeitic and solid tumors. ..
- Enhancing Information Dissemination on Health Disparities Research: A DatabaseBill Bowers; Fiscal Year: 2010..We intend to complete this in a format to be ready for use and to be returned to NCMHD in total at the end of the grant period. ..
- Eating for Life: Dietary Behaviors Among Long Term Cancer SurvivorsKatherine Clegg Smith; Fiscal Year: 2012..and history and survivorship identity with current dietary data from a sample of 60 long term survivors of non Hodgkin lymphoma, breast and prostate cancer...
- Molecular targets in diffuse large B cell lymphomaSandeep Dave; Fiscal Year: 2013Diffuse large B cell lymphoma (DLBCL) is the most common form of non Hodgkin lymphoma, with an annual incidence of 25,000 in the United States and nearly 10,000 deaths per year attributable to the disease...
- Ecological and Health Consequences of the Vietnam WarLinda Schwartz; Fiscal Year: 2001..Protection Agency (EPA) as a "known carcinogen," the discussion of rare cancers, Soft Tissue Sarcomas, and Non Hodgkin Lymphoma and cancers of all sites combined will be a focal point of the program...
- Combined radio- and immunotherapy of aggressive NHLWilliam A Wegener; Fiscal Year: 2013....
- HAIR DYE USE AND RISK OF NONHODGKINS LYMPHOMATongzhang Zheng; Fiscal Year: 2000..Statistical analyses will be performed using standard techniques to address the questions raised by the specific aims. ..
- Development of therapeutic monoclonal antibody to the bioactive lipid lysophosphaRosalia Matteo; Fiscal Year: 2009..Discovering the major determinants in cancer progression for the development of more efficacious therapies is therefore extremely important to society. ..
- Molecular Epidemiology of non-Hodgkin Lymphoma SurvivalJames R Cerhan; Fiscal Year: 2010..Host genetics may also lead to a better understanding of NHL pathophysiology that could lead to new approaches to improve the survival of NHL patients. ..
- DETERMINANTS OF HEPATITIS C & E MORBIDITY IN EGYPTGeorge Strickland; Fiscal Year: 2002..abstract_text> ..
- DETERMINANTS OF HEPATITIS C & E MORBIDITY IN EGYPTGeorge Strickland; Fiscal Year: 2004..abstract_text> ..
- Vitamin D, alcohol, and risk of lymphomas in a prospective cohort of womenELLEN TING YEE CHANG; Fiscal Year: 2010....
- Race-Specific Occupational Risk Factors for CancerNATHANIEL BRIGGS; Fiscal Year: 2004..abstract_text> ..
- PREVALENCE AND PATHOLOGIC BURDEN OF HTLV-II INFECTIONBrian Hjelle; Fiscal Year: 1992..The goal of this study is to define any potential of HTLV-II to induce lymphoid neoplasms in the HTLV-II-endemic populations...
- Outcomes of Curable Cancers in Vulnerable PopulationsSiran Koroukian; Fiscal Year: 2009..We will examine survival outcomes by Medicaid status;and among Medicaid beneficiaries, survival and cure rates will be evaluated in the presence or absence of mental and/or physical comorbid conditions. ..
- STRUCTURES OF ANTIBIOTICS AND RELATED COMPOUNDSRobert Coates; Fiscal Year: 2003....
- PATHOGENESIS OF H PYLORI INDUCED GASTRIC INFLAMMATIONRichard Peek; Fiscal Year: 2000..pylori virulence genes on cytokine production in vitro. ..
- PHASE I STUDY OF ANTICD20/STREPTAVIDINHazel Breitz; Fiscal Year: 2001..These phase I studies will define schema and doses for a subsequent phase II study of PRIT using the fusion anti-CD20/streptavidin protein in patients with CD20+ non-Hodgkin's lymphoma. ..